Search Results
Sep 02, 2026, 02:04 ET Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
require simultaneous binding to a predefined multi-antigen tumor signature to trigger T cell activation. This logic-gated approach represents a novel drug class aimed at improving treatment precision, reducing activation in healthy tissues and potentially broadening the therapeutic window.Evotec's
More news about: Evotec SE
Sep 01, 2026, 12:37 ET Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline
stock price plummeted over 56%. May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and
More news about: Hagens Berman Sobol Shapiro LLP
Sep 01, 2026, 12:00 ET INVESTOR DEADLINE: Capricor Therapeutics, Inc. (CAPR) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline
CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory
More news about: Hagens Berman Sobol Shapiro LLP
Sep 01, 2026, 12:00 ET EvoMap Open-Sources AutoResearch, Giving AI Agents a Way to Test Their Own Research Ideas
actually works" is a critical step toward more autonomous research.The same principle could eventually extend beyond AI to areas such as drug discovery, materials science and engineering, where research ideas can be evaluated through simulations or physical experiments. The potential is
More news about: EvoMap
Sep 01, 2026, 11:37 ET A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
for dermal fillers, body-contouring devices, skin-tightening treatments, and other procedures aimed at restoring volume and firmness. With the obesity-drug market projected to reach roughly US$100 billion in annual sales by 2030, the pool of patients who may seek aesthetic follow-up treatments is expanding
More news about: Equity Insider
Sep 01, 2026, 10:37 ET Naväge® Introduces Its Most Advanced Nose Cleaner Yet for Fast, Smart Congestion Relief
30 seconds[2].Is the Naväge Advanced Nose Cleaner drug-free?Yes. The Advanced Nose Cleaner uses Naväge SaltPod® capsules with distilled or sterile water to provide a 100% drug-free saline rinse.How do you clean the Naväge Advanced Nose Cleaner?The
More news about: Naväge Nasal Care
Sep 01, 2026, 10:31 ET The Oral PCSK9 Inhibitor Market Enters High-Growth Phase Owing to the Approval of Merck's LIPFENDRA and the Emergence of Oral PCSK9 Inhibitor Drugs, Including, AstraZeneca's AZD0780, Aqur's AQR-008, and Others | DelveInsight
barriers associated with injectable PCSK9 therapies, potentially expanding the overall PCSK9 treatment population.Advances in PCSK9-Targeted Drug Development: Innovations across monoclonal antibodies, small molecules, oral inhibitors, and RNA-based approaches are broadening the PCSK9 therapeutic
More news about: DelveInsight Business Research, LLP
Sep 01, 2026, 10:15 ET Local Father Launches High-Performance Mineral Sunscreen to Solve Youth Sports Frustrations
product required rigorous professional oversight, Stoneking partnered with an established manufacturer to ensure full compliance with strict Food and Drug Administration guidelines. The final result is an innovative, high-performance mineral sunscreen manufactured entirely in the United States. It provides
More news about: Venture Performance Sunscreen
Sep 01, 2026, 10:01 ET Blood Cancer Treatment Advances Have Saved Nearly 26 Million Years of Life Over Past 75 Years
therapies.Future progress will rely on innovative combinations, precision medicines and next-generation immunotherapies, including bispecific antibodies, antibody-drug conjugates, and cellular therapies.Progress varies significantly by cancer typeSubstantial improvement in
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
Sep 01, 2026, 10:00 ET Meridian, Eye Care For Detroit to Distribute Nearly 3,800 Reading Glasses to Michigan Seniors
families, children, seniors and individuals with complex medical needs primarily through Medicaid (Meridian), Medicare Advantage and Medicare Prescription Drug Plans (Wellcare), Medicare-Medicaid Plans, including Wellcare Meridian Dual Align (HMO D-SNP), and the Health Insurance Marketplace (Ambetter from Meridian).
More news about: Meridian of Michigan
Sep 01, 2026, 09:27 ET Medibyt Receives FDA 510(k) Clearance for CPETWise, Advancing Cardiopulmonary Exercise Test Analysis and Interpretation
digital health company focused on transforming cardiopulmonary diagnostics through intelligent automation, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to CPETWise
More news about: Medibyt
Sep 01, 2026, 09:11 ET Victory Square Technologies Reports First-Half 2026 Revenue of $53.0 Million and Net Income of $6.5 Million
Hydreight continues to scale the healthcare infrastructure we have spent years helping build. Insu Therapeutics is advancing the development of its buccal drug-delivery platform, and Pawsible is applying our venture-building approach to opportunities within companion-animal health.""Our approach has
More news about: Victory Square Technologies Inc
Sep 01, 2026, 09:05 ET BioMarin Announces Close of the Alesta Therapeutics Acquisition
a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound
More news about: BioMarin Pharmaceutical Inc.
Sep 01, 2026, 09:00 ET Eclipsebio expands its RNA characterization capabilities with multi-attribute nanopore-based sequencing assay eSTRAND RNA QC™
nanopore-based RNA characterization assay.Traditional analytical tools provide limited information on RNA characterization, making it difficult for drug developers to determine the best manufacturing selections for an effective therapeutic. eSTRAND RNA QC uses nanopore-based direct RNA sequencing to
More news about: Eclipsebio
Sep 01, 2026, 09:00 ET SugarbearPRO® Launches Hair Prenatal, a Hair-Focused Gummy for Before, During and After Pregnancy
sugarbearpro.com.*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.About SugarbearPRO®:SugarbearPRO
More news about: SugarbearPRO
Sep 01, 2026, 09:00 ET BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
laboratory-developed tests (LDTs) performed in a CLIA-certified and CAP-accredited laboratory. These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test performance may vary based on factors including cancer type, disease burden, treatment, and specimen characteristics.Forward-Looking
More news about: BillionToOne
Sep 01, 2026, 08:45 ET Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
www.groupedevonian.comReferenceBotanical Drug Development Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2016 Pharmaceutical Quality/CMCForward-Looking
More news about: Devonian Health Group Inc.
Sep 01, 2026, 08:30 ET Lymphoma Research Foundation Announces International T-Cell Lymphomas Consortium
challenging lymphomas to diagnose and treat. Compared with more common forms of lymphoma, they have historically received less research funding and drug development, resulting in fewer approved therapies and limited treatment options for patients."Progress in rare diseases requires sustained investment,
More news about: Lymphoma Research Foundation
Sep 01, 2026, 08:05 ET SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
to the human body to cleanse, beautify, promote attractiveness, and alter appearances. These SkinMedica® products are not intended to be drug products that diagnose, treat, cure, or prevent any disease or condition. These products have not been approved by the FDA and the statements have not
More news about: AbbVie
Sep 01, 2026, 08:04 ET SHARx Urges HR and CFO Leaders to Rethink the True Cost of Pharmacy Benefits
Index—June 2026. U.S. Department of Labor. bls.gov/news.release/eci.nr0.htmBrown, C. (2026, August 17). Why prescription drug prices are plunging. Axios. axios.com/2026/08/17/drug-prices-medicare-trumpNesbitt, J. (2026, July 15). Rising health costs push employers to rethink benefits strategies.
More news about: SHARx
Sep 01, 2026, 08:00 ET QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
electrostatic interaction energy, a major factor in how tightly a drug candidate binds to its target, at complex metal centers such as the iron site in P450nor, could improve candidate ranking and help identify metabolic risks earlier in the drug-discovery process."Running the same hybrid workflow on
More news about: QC Ware Corp.
Sep 01, 2026, 08:00 ET QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
electrostatic interaction energy, a major factor in how tightly a drug candidate binds to its target, at complex metal centers such as the iron site in P450nor, could improve candidate ranking and help identify metabolic risks earlier in the drug-discovery process."Running the same hybrid workflow on
More news about: QC Ware Corp.
Sep 01, 2026, 08:00 ET DISA Global Solutions Expands Compliance Capabilities with Acquisition of TEAM Companies
TEAM and DISA serve many of the same industries and share a commitment to helping employers maintain safe, compliant workplaces.In addition to drug testing, background screening, occupational health, and training services, TEAM provides contractor compliance monitoring through Alert, its proprietary
More news about: DISA Global Solutions
Sep 01, 2026, 08:00 ET Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
manufacturing. Manufacturing activities are expected to include process optimization, scale-up, analytical qualification, potency assay development, and drug product manufacturing in a cGMP-compliant facility.In Type 1 diabetes, Genprex's candidate is designed to transform pancreatic alpha cells into
More news about: Andelyn Biosciences
Sep 01, 2026, 08:00 ET Pyrotech Therapeutics Doses First Subject in Phase 1 Study of PTT-121, the World's First Selective GSDMD Inhibitor to Enter Clinical Development
long been regarded as the holy grail of pyroptosis drug development — a target of extraordinary therapeutic potential that defied conventional medicinal chemistry approaches. By achieving this milestone, we are not only validating our proprietary drug discovery platform but also opening an entirely new
More news about: Pyrotech Therapeutics